Feb

2011

Chimerix, Inc.: Series F $45M

Posted in I - Series F, Q - 1Q11, R - SOUTH EAST, X - Antiviral, X - CMV, XX - NC

Chimerix (Durham, NC) a clinical-stage pharma company developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $45M Series F financing. Participants include Pappas Ventures, Morningside Group, Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

Jan

2011

ViroXis Corp.: Series A $2.5M

Posted in I - Series A, Q - 4Q10, R - SOUTH WEST, X - Antiviral, X - HPV, XX - TX

ViroXis (San Antonio, TX) a development stage biopharmaceutical company focused on antiviral treatment of HPV associated skin warts, closed a $2.5M Series A financing. Participants include Texas Emerging Technology Fund.

Dec

2010

Beech Tree Labs, Inc.: Series B $7M

Posted in I - Series B, Q - 4Q10, R - NORTH EAST, X - Antiviral, X - HSV, X - Influenza, XX - RI

Beech Tree Labs (Providence, RI) a clinical-stage antiviral company focused on influenza and herpes, closed a $7M Series B financing. Participants were not identified.

Oct

2010

Tobria Therapeutics, Inc.: Series B $31M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Antiviral, X - HIV, X - Inflammation, XX - NJ

Tobira Therapeutics (Manalapan, NJ) a clinical-stage biopharmaceutical company focused on antivirals for HIV and inflammation, closed a $31M B financing. Participants include Novo Ventures, Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

Aug

2010

Visterra, Inc.: Series A $6M

Posted in I - Series A, Q - 3Q10, R - NORTH WEST, X - Antiviral, X - Influenza, X - Vaccines, XX - MA

Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

Apr

2010

HemaQuest Pharmaceuticals, Inc. Series B $12M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Antiviral, X - EBV, X - HIV, X - HPV, X - Hemoglobin, X - Sickle Cell, XX - MA

HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

Apr

2010

AiCuris, GmbH: Series B $74.8M

Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Antibacterial, X - Antiinfective, X - Antiviral, X - CMV, X - HIV, X - Hepatitis B, X - Hepatitis C

AiCuris (Germany) a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria, closed a $74.8M Series B financing. Participants include Santo Holding and Bayer Healthcare.

Oct

2009

Chimerix, Inc.: Series E $16M

Posted in I - Series E, Q - 3Q09, R - SOUTH EAST, X - Antiviral, X - CMV, XX - NC

Chimerix (Durham, NC) a clinical-stage developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $16M Series E financing. Participants include Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company.

Oct

2009

3-V Biosciences, Inc.: Series B $30M

Posted in I - Series B, Q - 3Q09, R - WEST, X - Antiviral, X - RNAi, XX - CA

3-V Biosciences (Palo Alto, CA) a preclinical-stage biopharma company focused on broad-spectrum antivirals for respiratory viral infections, closed a $30M Series B financing. Participants include New Enterprise Associates, The Column Group and Kleiner Perkins Caulfield & Byers.

Jul

2009

Alios BioPharma, Inc.: Series A $8M

Posted in I - Series A, Q - 2Q09, R - WEST, X - Antiviral, X - Therapeutic Platform, XX - CA

Alios BioPharma (San Francisco, CA) a preclinical-stage small molecule and protein therapeutics company focused on viral disease via innate immune modulation, closed a $8M Series A financing bring the total round to $32M. Participants include SR One, Novo Ventures, Novartis Venture Fund and Roche Venture Fund.

Mar

2009

Kenta Biotech, Ltd.: Series B $10M

Posted in I - Series B, Q - 1Q09, R - INTERNATIONAL, X - Antibacterial, X - Antibody, X - Antiinfective, X - Antiviral, X - Pneumonia

Kenta Biotech (Switzerland) clinical-stage developer of antibacterial and antiviral antibodies targeting Pseudomonas aeruginosa caused nosocomial pneumonia closed a $10M Series B financing. Participants in this round have not been identified.

Feb

2009

Alios BioPharma, Inc.: Series A $8.4M

Posted in I - Series A, Q - 1Q09, R - WEST, X - Antiviral, XX - CA

Alios BioPharma (San Francisco, CA) a pre-clinical biotechnology company developing small molecule activators of innate immunity antiviral pathways, closed a $8.4M Series A financing. Participants include Novo A/S, Novartis BioVentures and Roche Venture Fund.

Dec

2008

Okapi Sciences, NV: Series A $10.8M

Posted in I - Series A, Q - 4Q08, R - INTERNATIONAL, X - Antiviral, X - Veterinary

Okapi Sciences (Belgium) early-stage developer of antiviral drugs for veterinary applications, closed a $10.8M Series A financing. Participants include Agri Investment Fund, Dutch Thuja Capital, Fortis Private Equity Arkimedes, KBC Arkiv, Vinnof, Gemma Frisius Fund, K.U.Leuven and Spinventure.

« Previous Entries

to top of page...